Lymphoma Research Foundation Hosting Major Lymphoma Forum Nov 9-11

The Lymphoma Research Foundation (LRF), the nation’s largest non-profit organization devoted entirely to lymphoma research, outreach and awareness, will be hosting its 17th annual North American Educational Forum on Lymphoma in Manhattan Beach, California, from November 9th to November 11th, 2012.

This Forum is a two-and-a-half day program that provides critical information on treatment options, support issues, clinical trials, and the latest advances in lymphoma research. It is widely considered to be the most comprehensive lymphoma-specific education conference in North America.

This year's Forum co-chairs are:

-- Bruce Cheson, MD, FACP, FAAAS – Deputy Chief of the Division of Hematology-Oncology and Head of Hematology at the Lombardi Comprehensive Cancer Center at Georgetown University Hospital

-- John Leonard, MD – the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology and Associate Dean for Clinical Research at Weill Cornell Medical College

"As co-chair of this year’s Educational Forum, I am honored to bring together and present with such renowned experts in the field of lymphoma," said Dr. Leonard.

"This Forum is so important for patients, survivors and caregivers because it enables them to gain a better understanding of their particular subtype of lymphoma and the current treatment options available so that they can become active participants in their care."

This year’s Forum will feature information on disease and treatment and offer unique networking opportunities for those in attendance to meet others with the same lymphoma subtype.

"The Lymphoma Research Foundation’s Educational Forum provides an opportunity for members of the lymphoma community to learn about the disease from some of the world’s leading lymphoma experts and to meet others with the same subtype of the disease," said Brian Tomlinson, LRF’s Chief Program Officer.

"With more than 70 subtypes, lymphoma is a complex diagnosis; the ability the Forum affords to ask questions of such prominent experts and to meet others who have had similar experiences is invaluable for patients and their loved ones."

The Forum is open to all members of the public. There is a $50 registration fee. Information on registration and other aspects of the Forum can be found HERE or by calling (800)500-9976.

Source: LRF

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap